(Q38030991)

27 August 2017

Potential for statins in the chemoprevention and management of hepatocellular carcinoma (English)

1 reference

27 August 2017

Amedeo Lonardo

1

1 reference

PubMed ID

22849701

27 August 2017

Paola Loria

series ordinal

2

1 reference

PubMed ID

22849701

27 August 2017

language of work or name

1 reference

1 November 2012

1 reference

Journal of Gastroenterology and Hepatology

27 August 2017

1 reference

27 August 2017

27

1 reference

27 August 2017

11

1 reference

27 August 2017

1654-1664

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

27 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

A historical perspective on the discovery of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins, stem cells, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hepatocarcinogenesis and ceramide/cholesterol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Altered lipid profile, oxidative status and hepatitis B virus interactions in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hepatitis C Virus Stabilizes Hypoxia-Inducible Factor 1 and Stimulates the Synthesis of Vascular Endothelial Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

STAT 3 as a target for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Rho GTPases in cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Proteins regulating Ras and its relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Drug insight: statins and gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins in liver disease: a molehill, an iceberg, or neither?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Cancer risk among statin users: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Coffee and its consumption: benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Levels of circulating endothelin-1 and nitrates/nitrites in patients with virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Two Decades of Advances in Hepatocellular Carcinoma Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07232.X

10.1111/J.1440-1746.2012.07232.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22849701